Anrukinzumab

Names

[ Name ]:
Anrukinzumab

Biological Activity

[Description]:

Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

[Target]

IL-13[1][2][3].

[In Vivo]

Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) 减少食蟹猕猴肺部炎症模型中的肺部炎症[1]。 Animal Model: Adult male cynomolgus monkeys (6 to 10 kg; cynomolgus monkey model of lung inflammation)[1]. Dosage: 10 mg/kg Administration: Intravenous infusion; single Result: Reduced total BAL cell count, eosinophil number, and neutrophil number. Reduced the levels of eotaxin and RANTES in BAL fluid.

[References]

[1]. Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7.

[2]. Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900.

[3]. Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.